Bejelentkezés Regisztrálj ingyen

Last updated: 29 April 2024 at 12:12pm EST

Donald Landry Net Worth




The estimated Net Worth of Donald W Landry is at least $766 ezer dollars as of 25 February 2016. Donald Landry owns over 2,100 units of Sensient Technologies stock worth over $567,764 and over the last 12 years he sold SXT stock worth over $0. In addition, he makes $197,827 as Independent Director at Sensient Technologies.

Donald Landry SXT stock SEC Form 4 insiders trading

Donald has made over 1 trades of the Sensient Technologies stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,100 units of SXT stock worth $154,644 on 25 February 2016.

The largest trade he's ever made was exercising 2,100 units of Sensient Technologies stock on 25 February 2016 worth over $154,644. On average, Donald trades about 100 units every 0 days since 2013. As of 25 February 2016 he still owns at least 7,710 units of Sensient Technologies stock.

You can see the complete history of Donald Landry stock trades at the bottom of the page.





Donald Landry biography

Dr. Donald W. Landry M.D. Ph.D. serves as Independent Director of the Company. Dr. Landry is the Samuel Bard Professor and Chair of the Department of Medicine at Columbia University’s College of Physicians and Surgeons. He also serves as its Director of the Division of Experimental Therapeutics and Physician-in-Chief for the Medical Service at New York Presbyterian Hospital/Columbia Medical Center. Dr. Landry has been a member of the faculty of Columbia University since 1985. At Columbia, Dr. Landry developed the first artificial enzyme to degrade cocaine and his report in Science was voted one of top 25 papers in the world for 1993 by the American Chemical Society. His discovery that vasopressin can be used to treat vasodilatory shock fundamentally changed intensive care medicine. He also pioneered an embryo-sparing approach to the generation of human embryonic stem cells. Dr. Landry has been a director of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) since October 2011. Between June 2007 and October 2011, Dr. Landry served as a founding director of Tonix Pharmaceuticals, Inc., a wholly-owned subsidiary of Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a publicly traded company that develops next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. Dr. Landry was co-founder and has been a member of L&L Technologies LLC since 1996. L&L Technologies LLC was formed to develop medications for central nervous system conditions. Dr. Landry was also a co-founder of Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including very low dose (VLD) cyclobenzaprine for fibromyalgia syndrome. Co-founder of Vela Pharmaceuticals, a private company that developed several drugs for central nervous system disorders, including very low dose (VLD) cyclobenzaprine for fibromyalgia syndrome.

What is the salary of Donald Landry?

As the Independent Director of Sensient Technologies, the total compensation of Donald Landry at Sensient Technologies is $197,827. There are 17 executives at Sensient Technologies getting paid more, with Paul Manning having the highest compensation of $5,819,140.



How old is Donald Landry?

Donald Landry is 65, he's been the Independent Director of Sensient Technologies since 2015. There are 4 older and 20 younger executives at Sensient Technologies. The oldest executive at Sensient Technologies Corp. is Edward Cichurski, 78, who is the Independent Director.

What's Donald Landry's mailing address?

Donald's mailing address filed with the SEC is 509 Madison Ave #306, New York, NY 10022, USA.

Insiders trading at Sensient Technologies

Over the last 22 years, insiders at Sensient Technologies have traded over $506,130,949 worth of Sensient Technologies stock and bought 2,091,019 units worth $179,367,326 . The most active insiders traders include Investment Pte Ltd Freemont..., Investment Pte Ltd Haldor F... és Kenneth P Manning. On average, Sensient Technologies executives and independent directors trade stock every 18 days with the average trade being worth of $2,140,788. The most recent stock trade was executed by Gebhardt Deborah Mc Keithan on 14 August 2024, trading 2,000 units of SXT stock currently worth $142,160.



What does Sensient Technologies do?

we bring life to products. our name communicates what we do: enhance sensory experiences through specialized ingredients, delivered through proprietary technologies. sensient technologies corporation is a leading global developer, manufacturer and marketer of colors, flavors and fragrances. sensient uses advanced proprietary technologies at facilities around the world to produce a broad range of innovative products. we provide customized food and beverage systems, pharmaceutical colors and coatings, cosmetic and personal care formulations, inkjet and specialty inks and colors, and other fine chemicals to most of the world’s best-known consumer and industrial companies. sensient is in the business of innovation. all of our units emphasize technology-based products that provide a competitive advantage. we serve our customers by continuously delivering innovation and streamlined product-development expertise, helping them extend their existing brands as well as create new products. learn



What does Sensient Technologies's logo look like?

Sensient Technologies Corp. logo

Complete history of Donald Landry stock trades at Tonix Pharmaceuticals Corp és Sensient Technologies

Dátum
#
Cég
 Az érdekelt
Trans.
Tranzakció
 Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
25 Feb 2016 TNXP Tonix Pharmaceuticals Holding Corp Donald W Landry
Rendező
 Opció Gyakorlat 2,100 $28.00 $58,800
25 Feb 2016
7,710 ↗


Sensient Technologies executives and stock owners

Sensient Technologies executives and other stock owners filed with the SEC include: